Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Nephrology
Published in: BMC Nephrology 1/2019

Open Access 01-12-2019 | Acute Kidney Injury | Research article

The potential effects of anabolic-androgenic steroids and growth hormone as commonly used sport supplements on the kidney: a systematic review

Authors: Dorna Davani-Davari, Iman Karimzadeh, Hossein Khalili

Published in: BMC Nephrology | Issue 1/2019

Login to get access

Abstract

Background

Anabolic-androgenic steroids and growth hormone are among the most commonly used supplements by sportsmen and sportswomen. The aim of this systematic review is to collect and report available data about renal safety of anabolic-androgenic steroids and growth hormone (GH).

Methods

The search strategy was in accordance with the PRISMA guideline. Seven databases such as Scopus, Medline, Embase, and ISI Web of Knowledge were searched using keywords, such as “growth hormone”, “anabolic-androgenic steroids”, and “kidney injury”. Articles published from 1950 to December 2017 were considered. Randomized clinical trials, prospective or retrospective human studies, case series as well as case reports, and experimental (in vivo) studies were included. Twenty one clinical and experimental articles were selected (12 for anabolic-androgenic steroids and 9 for GH).

Results

Anabolic-androgenic steroids can affect the kidney in different aspects. They can induce or aggravate acute kidney injury, chronic kidney disease, and glomerular toxicity. These adverse effects are mediated through pathways such as stimulating renin-angiotensin-aldosterone system, enhancing the production of endothelin, producing reactive oxygen species, over-expression of pro-fibrotic and pro-apoptotic mediators (e.g., TGF-β1), as well as inflammatory cytokines (e.g., TNF-α, IL-1b, and IL-6). Although GH may affect the kidney in different aspects, such as size, glomerular filtration rate, and tubule functions, either directly or indirectly, there is no conclusive clinical evidence about its detrimental effects on the kidney in athletes and body builders.

Conclusion

Evidence regarding effects of anabolic-androgenic steroids exists; However, GH’s exact effect on the kidney at doses used by athletes and body builders has not yet been clarified. Cohort clinical studies with long-term follow-up are warranted in this regard.
Literature
1.
Maughan RJ, editor. Sports nutrition. Oxford: Wiley-Blackwell; 2014.
2.
Ehrnborg C, Rosén T. The psychology behind doping in sport. Growth Hormon IGF Res. 2009;19:285–7.CrossRef
3.
Supplement Business Report 2016. New York, NY: Penton Nutrition Business Journal 2017.
4.
Lieberman HR, Marriott BP, Williams C, Judelson DA, Glickman EL, Geiselman PJ, Dotson L, Mahoney CR. Patterns of dietary supplement use among college students. Clin Nutr. 2015;34:976–85.PubMedCrossRef
5.
Rexroat R. NCAA national study of substance use habits of college student-athletes. Natl Coll Athl Assoc. 2014:1–101.
6.
Perry PJ, Lund BC, Deninger MJ, Kutscher EC, Schneider J. Anabolic steroid use in weightlifters and bodybuilders: an internet survey of drug utilization. Clin J Sport Med. 2005;15:326–30.PubMedCrossRef
7.
Daher EDF, Martiniano LVM, Lima LLL, Leite Filho NCV, de Oliveira Souza LE, Fernandes PHPD, da Silva SL, da Silva Junior GB. Acute kidney injury due to excessive and prolonged intramuscular injection of veterinary supplements containing vitamins a, D and E: a series of 16 cases. nefrologia. 2017;37:61–7.CrossRef
8.
Timcheh-Hariri A, Balali-Mood M, Aryan E, Sadeghi M, Riahi-Zanjani B. Toxic hepatitis in a group of 20 male body-builders taking dietary supplements. Food Chem Toxicol. 2012;50:3826–32.PubMedCrossRef
9.
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6:e1000100.PubMedPubMedCentralCrossRef
10.
Fortunato RS, Rosenthal D, DPd C. Abuse of anabolic steroids and its impact on thyroid function. Arq Bras Endocrinol Metabol. 2007;51:1417–24.PubMedCrossRef
11.
Sjöqvist F, Garle M, Rane A. Use of doping agents, particularly anabolic steroids, in sports and society. Lancet. 2008;371:1872–82.PubMedCrossRef
12.
Iriart JAB, TMd A. Body-building, steroid use, and risk perception among young body-builders from a low-income neighborhood in the city of Salvador, Bahia state, Brazil. Cad Saude Publica. 2002;18:1379–87.PubMedCrossRef
13.
Kanayama G, Pope HG. History and epidemiology of anabolic androgens in athletes and non-athletes. Mol Cell Endocrinol. 2017.
14.
Santos AF, Mendonça PMH, Santos LA, Silva NF, Tavares JKL. Anabolic steroids: concepts according to muscular activity practisers in Aracaju (SE). Psicologia em Estudo. 2006;11:371–80.CrossRef
15.
Johnson CA. Use of androgens in patients with renal failure. In: Seminars in dialysis: Wiley Online Library; 2000. p. 36–9.
16.
Chapter 3: Use of ESAs and other agents to treat anemia in CKD. Kidney Int Suppl (2011). 2012;2:299–310.
17.
Bird SR, Goebel C, Burke LM, Greaves RF. Doping in sport and exercise: anabolic, ergogenic, health and clinical issues. Ann Clin Biochem. 2016;53:196–221.PubMedCrossRef
18.
Goldman A, Basaria S. Adverse health effects of androgen use. Mol Cell Endocrinol. 2017.
19.
Luciano RL, Castano E, Moeckel G, Perazella MA. Bile acid nephropathy in a bodybuilder abusing an anabolic androgenic steroid. Am J Kidney Dis. 2014;64:473–6.PubMedCrossRef
20.
Daher EF, Júnior GBS, Queiroz AL, Ramos LM, Santos SQ, Barreto DM, Guimarães AAC, Barbosa CA, Franco LM, Patrocínio RM. Acute kidney injury due to anabolic steroid and vitamin supplement abuse: report of two cases and a literature review. Int Urol Nephrol. 2009;41:717–23.PubMedCrossRef
21.
Libório AB, Nasserala JC, Gondim AS, Daher EF. The case| renal failure in a bodybuilder athlete. Kidney Int. 2014;85:1247–8.PubMedCrossRef
22.
Almukhtar SE, Abbas AA, Muhealdeen DN, Hughson MD. Acute kidney injury associated with androgenic steroids and nutritional supplements in bodybuilders. Clin Kidney J. 2015;8:415–9.PubMedPubMedCentralCrossRef
23.
Tabatabaee SM, Elahi R, Savaj S. Bile cast nephropathy due to cholestatic jaundice after using stanozolol in 2 amateur bodybuilders. Iran J Kidney Dis. 2015:9.
24.
Alkhunaizi AM, ElTigani MA, Rabah RS, Nasr SH. Acute bile nephropathy secondary to anabolic steroids. Clin Nephrol. 2016;85:121–6.PubMedCrossRef
25.
Tsuji S, Sugiura M, Tsutsumi S, Yamada H. Sex differences in the excretion levels of traditional and novel urinary biomarkers of nephrotoxicity in rats. J Toxicol Sci. 2017;42:615–27.PubMedCrossRef
26.
Schaefer F, Mehls O, Ritz E. New insights into endocrine disturbances of chronic renal failure. Miner Electrolyte Metab. 1991;18:169–73.
27.
Dousdampanis P, Trigka K, Fourtounas C, Bargman JM. Role of testosterone in the pathogenesis, progression, prognosis and comorbidity of men with chronic kidney disease. Ther Apher Dial. 2014;18:220–30.PubMed
28.
Metcalfe PD, Leslie JA, Campbell MT, Meldrum DR, Hile KL, Meldrum KK. Testosterone exacerbates obstructive renal injury by stimulating TNF-α production and increasing proapoptotic and profibrotic signaling. Am J Physiol Endocrinol Metab. 2008;294:E435–43.PubMedCrossRef
29.
Quan A, Chakravarty S, Chen J-K, Chen J-C, Loleh S, Saini N, Harris RC, Capdevila J, Quigley R. Androgens augment proximal tubule transport. Am J Physiol Ren Physiol. 2004;287:F452–9.CrossRef
30.
Alexander BT, Cockrell KL, Rinewalt AN, Herrington JN, Granger JP. Enhanced renal expression of preproendothelin mRNA during chronic angiotensin II hypertension. Am J Phys Regul Integr Comp Phys. 2001;280:R1388–92.
31.
Song J, Eyster KM, Kost CK, Kjellsen B, Martin DS. Involvement of protein kinase C-CPI-17 in androgen modulation of angiotensin II-renal vasoconstriction. Cardiovasc Res. 2010;85:614–21.PubMedCrossRef
32.
Mukai Y, Shimokawa H, Matoba T, Kandabashi T, Satoh S, Hiroki J, Kaibuchi K, Takeshita A. Involvement of rho-kinase in hypertensive vascular disease: a novel therapeutic target in hypertension. FASEB J. 2001;15:1062–4.PubMedCrossRef
33.
Liu B, Ely D. Testosterone increases: sodium reabsorption, blood pressure, and renal pathology in female spontaneously hypertensive rats on a high sodium diet. Adv Pharmacol Sci. 2011;2011.
34.
Loh SY, Giribabu N, Gholami K, Salleh N. Effects of testosterone on mean arterial pressure and aquaporin (AQP)-1, 2, 3, 4, 6 and 7 expressions in the kidney of orchidectomized, adult male Sprague-Dawley rats. Arch Biochem Biophys. 2017;614:41–9.PubMedCrossRef
35.
Svartberg J. Epidemiology: testosterone and the metabolic syndrome. Int J Impot Res. 2007;19:124–8.PubMedCrossRef
36.
Svartberg J, von Muhlen D, Schirmer H, Barrett-Connor E, Sundfjord J, Jorde R. Association of endogenous testosterone with blood pressure and left ventricular mass in men. The Tromso study. Eur J Endocrinol. 2004;150:65–71.PubMedCrossRef
37.
Zitzmann M, Nieschlag E. Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men. J Clin Endocrinol Metab. 2007;92:3844–53.PubMedCrossRef
38.
Kalk P, Thöne-Reineke C, Schwarz A, Godes M, Bauer C, Pfab T, Hocher B. Renal phenotype of ET-1 transgenic mice is modulated by androgens. Eur J Med Res. 2009;14:55.PubMedPubMedCentralCrossRef
39.
40.
Agarwal R. Chronic kidney disease is associated with oxidative stress independent of hypertension. Clin Nephrol. 2004;61:377–83.PubMedCrossRef
41.
Cho MH, Jung K-J, Jang H-S, Kim JI, Park KM. Orchiectomy attenuates kidney fibrosis after ureteral obstruction by reduction of oxidative stress in mice. Am J Nephrol. 2011;35:7–16.PubMedCrossRef
42.
Verzola D, Villaggio B, Procopio V, Gandolfo MT, Gianiorio F, Famà A, Tosetti F, Traverso P, Deferrari G, Garibotto G. Androgen-mediated apoptosis of kidney tubule cells: role of c-Jun amino terminal kinase. Biochem Biophys Res Commun. 2009;387:531–6.PubMedCrossRef
43.
D'agostino P, Milano S, Barbera C, Bella G, Rosa M, Ferlazzo V, Farruggio R, Miceli D, Miele M, Castagnetta L. Sex Hormones Modulate Inflammatory Mediators Produced by Macrophagesa. Ann N Y Acad Sci. 1999;876:426–9.PubMedCrossRef
44.
Li Z, Danis V, Brooks P. Effect of gonadal steroids on the production of IL-1 and IL-6 by blood mononuclear cells in vitro. Clin Exp Rheumatol. 1992;11:157–62.
45.
Gornstein RA, Lapp CA, Bustos-Valdes SM, Zamorano P. Androgens modulate interleukin-6 production by gingival fibroblasts in vitro. J Periodontol. 1999;70:604–9.PubMedCrossRef
46.
Culig Z. Androgen receptor cross-talk with cell signalling pathways. Growth Factors. 2004;22:179–84.PubMedCrossRef
47.
Delfino FJ, Boustead JN, Fix C, Walker WH. NF-κB and TNF-α stimulate androgen receptor expression in Sertoli cells. Mol Cell Endocrinol. 2003;201:1–12.PubMedCrossRef
48.
Doublier S, Lupia E, Catanuto P, Periera-Simon S, Xia X, Korach K, Berho M, Elliot SJ, Karl M. Testosterone and 17β-estradiol have opposite effects on podocyte apoptosis that precedes glomerulosclerosis in female estrogen receptor knockout mice. Kidney Int. 2011;79:404–13.PubMedCrossRef
49.
50.
Terada N, Arai Y, Kinukawa N, Yoshimura K, Terai A. Risk factors for renal cysts. BJU Int. 2004;93:1300–2.PubMedCrossRef
51.
Donadio JV, Torres VE, Velosa JA, Wagoner RD, Holley KE, Okamura M, Ilstrup DM, Chu C-P. Idiopathic membranous nephropathy: the natural history of untreated patients. Kidney Int. 1988;33:708–15.PubMedCrossRef
52.
Mangili R, Deferrari G, Di Mario U, Giampietro O, Navalesi R, Nosadini R, Rigamonti G, Spezia R, Crepaldi G, Group IMS. Arterial hypertension and microalbuminuria in IDDM: the Italian microalbuminuria study. Diabetologia. 1994;37:1015–24.PubMedCrossRef
53.
Maric C, Forsblom C, Thorn L, Wadén J, Groop P-H, Group FS. Association between testosterone, estradiol and sex hormone binding globulin levels in men with type 1 diabetes with nephropathy. Steroids. 2010;75:772–8.PubMedPubMedCentralCrossRef
54.
Manigrasso MB, Sawyer RT, Marbury DC, Flynn ER, Maric C. Inhibition of estradiol synthesis attenuates renal injury in male streptozotocin-induced diabetic rats. Am J Physiol Ren Physiol. 2011;301:F634–40.CrossRef
55.
Manigrasso MB, Sawyer RT, Hutchens ZM, Flynn ER, Maric-Bilkan C. Combined inhibition of aromatase activity and dihydrotestosterone supplementation attenuates renal injury in male streptozotocin (STZ)-induced diabetic rats. Am J Physiol Ren Physiol. 2012;302:F1203–9.CrossRef
56.
Xu Q, Prabhu A, Xu S, Manigrasso MB, Maric C. Dose-dependent effects of dihydrotestosterone in the streptozotocin-induced diabetic rat kidney. Am J Physiol Ren Physiol. 2009;297:F307–15.CrossRef
57.
Herlitz LC, Markowitz GS, Farris AB, Schwimmer JA, Stokes MB, Kunis C, Colvin RB, D'Agati VD. Development of focal segmental glomerulosclerosis after anabolic steroid abuse. J Am Soc Nephrol. 2010;21:163–72.PubMedPubMedCentralCrossRef
58.
Harrington P, Ali G, Chan A. The development of focal segmental glomerulosclerosis secondary to anabolic steroid abuse. BMJ Case Rep. 2011;2011:bcr0720114531.PubMedPubMedCentralCrossRef
59.
Turillazzi E, Perilli G, Di Paolo M, Neri M, Riezzo I, Fineschi V. Side effects of AAS abuse: an overview. Mini Rev Med Chem. 2011;11:374–89.PubMedCrossRef
60.
Drake WM, Howell SJ, Monson J, Shalet SM. Optimizing GH therapy in adults and children. Endocr Rev. 2001;22:425–50.PubMedCrossRef
61.
Bunderen CC, Varsseveld NC, Erfurth EM, Ket JC, Drent ML. Efficacy and safety of growth hormone treatment in adults with growth hormone deficiency: a systematic review of studies on morbidity. Clin Endocrinol. 2014;81:1–14.CrossRef
62.
Butler G. Indications for growth hormone therapy. Paediatr Child Health. 2007;17:356–60.CrossRef
63.
Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev. 1998;19:717–97.PubMed
64.
Chen EY, Liao Y-C, Smith DH, Barrera-Saldaña HA, Gelinas RE, Seeburg PH. The human growth hormone locus: nucleotide sequence, biology, and evolution. Genomics. 1989;4:479–97.PubMedCrossRef
65.
Baumann GP. Growth hormone doping in sports: a critical review of use and detection strategies. Endocr Rev. 2012;33:155–86.PubMedCrossRef
66.
Höybye C, Christiansen JS. Growth hormone replacement in adults–current standards and new perspectives. Best Pract Res Clin Endocrinol Metab. 2015;29:115–23.PubMedCrossRef
67.
Yarasheski KE, Campbell JA, Smith K, Rennie M, Holloszy J, Bier D. Effect of growth hormone and resistance exercise on muscle growth in young men. Am J Physiol. 1992;262:E261–7.PubMedCrossRef
68.
Yarasheski KE, Zachweija J, Angelopoulos TJ, Bier DM. Short-term growth hormone treatment does not increase muscle protein synthesis in experienced weight lifters. J Appl Physiol. 1993;74:3073–6.PubMedCrossRef
69.
Liu H, Bravata DM, Olkin I, Friedlander A, Liu V, Roberts B, Bendavid E, Saynina O, Salpeter SR, Garber AM. Systematic review: the effects of growth hormone on athletic performance. Ann Intern Med. 2008;148:747–58.PubMedCrossRef
70.
Meinhardt U, Nelson AE, Hansen JL, Birzniece V, Clifford D, Leung K-C, Graham K, Ho KK. The effects of growth hormone on body composition and physical performance in recreational athletes. Ann Intern Med. 2010;152:568–79.PubMedCrossRef
71.
72.
Pawlikowska-Haddal A. Growth hormone therapy with norditropin (somatropin) in growth hormone deficiency. Expert Opin Biol Ther. 2013;13:927–32.PubMedCrossRef
73.
Cutfield WS, Wilton P, Bennmarker H, Albertsson-Wikland K, Chatelain P, Ranke MB, Price DA. Incidence of diabetes mellitus and impaired glucose tolerance in children and adolescents receiving growth-hormone treatment. Lancet. 2000;355:610–3.PubMedCrossRef
74.
van Dijk M, Bannink EM, van Pareren YK, Mulder PG, Hokken-Koelega AC. Risk factors for diabetes mellitus type 2 and metabolic syndrome are comparable for previously growth hormone-treated young adults born small for gestational age (SGA) and untreated short SGA controls. J Clin Endocrinol Metabol. 2007;92:160–5.CrossRef
75.
Carel J-C, Butler G. Safety of recombinant human growth hormone. In: Hindmarsh PC, editor. Current indications for growth hormone therapy. Basel: Karger; 2010. p. 40–54.CrossRef
76.
Grunenwald S, Tack I, Chauveau D, Bennet A, Caron P. Impact of growth hormone hypersecretion on the adult human kidney. Ann Endocrinol (Paris). 2011;72:485–95.PubMedCrossRef
77.
Eskildsen P, Parving HH, Mogensen C, Christiansen JS. Kidney function in acromegaly. J Intern Med. 1979;205:79–82.
78.
Hirschberg R, Brunori G, Kopple JD, Guler H-P. Effects of insulin-like growth factor I on renal function in normal men. Kidney Int. 1993;43:387–97.PubMedCrossRef
79.
Hoogenberg K, Sluiter WI, Dullaart RP. Effect of growth hormone and insulin-like growth factor I on urinary albumin excretion: studies in acromegaly and growth hormone deficiency. Acta Endocrinol. 1993;129:151–7.CrossRef
80.
Gershberg H. Metabolic and renotropic effects of human growth hormone in-disease. J Clin Endocrinol Metab. 1960;20:1107–19.PubMedCrossRef
81.
Parving H-H, Noer I, Mogensen C, Svendsen PA. Kidney function in normal man during short-term growth hormone infusion. Acta Endocrinol. 1978;89:796–800.CrossRef
82.
Riedl M, Hass M, Oberbauer R, Gisinger J, Luger A, Mayer G. The effects of prolonged substitution of recombinant human growth hormone on renal functional reserve in growth hormone-deficient adults. J Am Soc Nephrol. 1995;6:1434–8.PubMed
83.
Gershberg H, Heinemann H, Stumpf H. Renal function studies and autopsy report in a patient with gigantism and acromegaly. J Clin Endocrinol Metab. 1957;17:377–85.PubMedCrossRef
84.
Falkheden T, Sjögren B. Extracellular fluid volume and renal function in pituitary insufficiency and acromegaly. Acta Endocrinol. 1964;46:80–8.CrossRef
85.
Auriemma RS, Galdiero M, De Martino MC, De Leo M, Grasso LF, Vitale P, Cozzolino A, Lombardi G, Colao A, Pivonello R. The kidney in acromegaly: renal structure and function in patients with acromegaly during active disease and 1 year after disease remission. Eur J Endocrinol. 2010;162:1035–42.PubMedCrossRef
86.
Mehls O, Irzynjec T, Ritz E, Eden S, Kovàcs G, Klaus G, Floege J, Mall G. Effects of rhGH and rhIGF-1 on renal growth and morphology. Kidney Int. 1993;44:1251–8.PubMedCrossRef
87.
Molon-Noblot S, Laroque P, Prahalada S, Stabinski LG, Peter CP, Duprat P, Van Zwieten MJ. Morphological changes in the kidney of dogs chronically exposed to exogenous growth hormone. Toxicol Pathol. 2000;28:510–7.PubMedCrossRef
88.
Khamaisi M, Søndergaard M, Segev Y, Dagnaes-Hansen F, Jensen TG, Landau D, Raz I, Flyvbjerg A. Differential effects on kidney and liver growth of a non-viral hGH-expression vector in hypophysectomized mice. Growth Hormon IGF Res. 2007;17:279–87.CrossRef
89.
Doi T, Striker LJ, Quaife C, Conti FG, Palmiter R, Behringer R, Brinster R, Striker G. Progressive glomerulosclerosis develops in transgenic mice chronically expressing growth hormone and growth hormone releasing factor but not in those expressing insulinlike growth factor-1. Am J Pathol. 1988;131:398.PubMedPubMedCentral
90.
Wanke R, Wolf E, Brem G, Hermanns W. Role of podocyte damage in the pathogenesis of glomerulosclerosis and tubulointerstitial lesions: findings in the growth hormone transgenic mouse model of progressive nephropathy. Verh Dtsch Ges Pathol. 2001;85:250–6.PubMed
91.
Doublier S, Seurin D, Fouqueray B, Verpont M-C, Callard P, Striker LJ, Striker GE, Binoux M, Baud L. Glomerulosclerosis in mice transgenic for human insulin-like growth factor-binding protein-1. Kidney Int. 2000;57:2299–307.PubMedCrossRef
92.
Newbold K, Howie A, Girling A, Kizaki T, Bryan R, Carey M. A simple method for assessment of glomerular size and its use in the study of kidneys in acromegaly and compensatory renal enlargement. J Pathol. 1989;158:139–46.PubMedCrossRef
93.
Christiansen JS, Gammelgaard J, Ørskov H, Andersen A, Telmer S, PARVING HH. Kidney function and size in normal subjects before and during growth hormone administration for one week. Eur J Clin Investig. 1981;11:487–90.CrossRef
94.
Link K, Bülow B, Westman K, Salmonsson EC, Eskilsson J, Erfurth EM. Low individualized growth hormone (GH) dose increased renal and cardiac growth in young adults with childhood onset GH deficiency. Clin Endocrinol. 2001;55:741–8.CrossRef
95.
Falkheden T, Wickbom I. Renal function and kidney size following hypophysectomy in man. Acta Endocrinol. 1965;48:348–54.CrossRef
96.
Doi T, Striker LJ, Gibson CC, Agodoa L, Brinster RL, Striker GE. Glomerular lesions in mice transgenic for growth hormone and insulinlike growth factor-II relationship between increased glomerular size and mesangial sclerosis. Am J Pathol. 1990;137:541.PubMedPubMedCentral
97.
Baldelli R, De Marinis L, Bianchi A, Pivonello R, Gasco V, Auriemma R, Pasimeni G, Cimino V, Appetecchia M, Maccario M. Microalbuminuria in insulin sensitivity in patients with growth hormone-secreting pituitary tumor. J Clin Endocrinol Metab. 2008;93:710–4.PubMedCrossRef
98.
Johannsson G, Sverrisdóttir YB, Ellegård L, Lundberg P-A, Herlitz H. GH increases extracellular volume by stimulating sodium reabsorption in the distal nephron and preventing pressure natriuresis. J Clin Endocrinol Metab. 2002;87:1743–9.PubMedCrossRef
99.
Hansen TK, Møller J, Thomsen K, Frandsen E, Dall R, Jørgensen JO, Christiansen JS. Effects of growth hormone on renal tubular handling of sodium in healthy humans. Am J Physiol Endocrinol Metab. 2001;281:E1326–32.PubMedCrossRef
100.
Dimke H, Flyvbjerg A, Frische S. Acute and chronic effects of growth hormone on renal regulation of electrolyte and water homeostasis. Growth Hormon IGF Res. 2007;17:353–68.CrossRef
101.
Bérard E, André JL, Guest G, Berthier F, Afanetti M, Cochat P, Broyer M. Long-term results of rhGH treatment in children with renal failure: experience of the French Society of Pediatric Nephrology. Pediatr Nephrol. 2008;23:2031.PubMedCrossRef
102.
Hodson EM, Willis NS, Craig JC. Growth hormone for children with chronic kidney disease. Cochrane Libr. 2012.
103.
Weir DR, Jackson JS, Sonnega A. National football league player care foundation study of retired NFL players. Ann Arbor: University of Michigan Institute for Social Research; 2009.
Metadata
Title
The potential effects of anabolic-androgenic steroids and growth hormone as commonly used sport supplements on the kidney: a systematic review
Authors
Dorna Davani-Davari
Iman Karimzadeh
Hossein Khalili
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2019
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-019-1384-0

Other articles of this Issue 1/2019

BMC Nephrology 1/2019 Go to the issue

Research article

Association between native T1 mapping of the kidney and renal fibrosis in patients with IgA nephropathy

Research article

Estimating the risk of acute kidney injury associated with use of diuretics and renin angiotensin aldosterone system inhibitors: A population based cohort study using the clinical practice research datalink

Research article

Induction therapy with thymoglobulin or interleukin-2 receptor antagonist for Chinese recipients of living donor renal transplantation: a retrospective study

Case report

PR3 vasculitis presenting with symptomatic splenic and renal infarction: a case report and literature review

Research article

Compositional alterations of gut microbiota in children with primary nephrotic syndrome after initial therapy

Research article

Acute kidney injury after liver resection in elderly patients

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits